

Date: 25th April, 2017

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives USFDA Final Approvals for Olmesartan Medoxomil Tablets and Olmesartan Medoxomil with Hydrochlorothiazide Tablets

With reference to the captioned subject, this is to inform the exchange that the Company has received U.S. Food & Drug Administration (FDA) final approvals for Olmesartan Medoxomil Tablets and Olmesartan Medoxomil with Hydrochlorothiazide Tablets. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

PRESS RELEASE

25th April, 2017, Vadodara, India

Alembic Pharmaceuticals receives USFDA Final Approval for Olmesartan Medoxomil Tablets and Olmesartan Medoxomil with Hydrochlorothiazide Tablets

Alembic Pharmaceuticals Limited today announced that the Company has received final approvals from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs) for Olmesartan Medoxomil Tablets, 5 mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5mg, 40/12.5mg and 40/25mg. The approved ANDAs are therapeutically equivalent to the reference listed drug products (RLDs) Benicar Tablets 5mg, 20mg and 40mg and Benicar HCT® Tablets, 20/12.5mg, 40/12.5mg and 40/25mg, of Daiichi Sankyo Inc. Approved ANDAs are indicated for the treatment of hypertension.

Benicar and Benicar HCT have an estimated market size of US\$ 1.8 billion for twelve months ending December 2016 according to IMS.

Alembic now has a total of 55 ANDA approvals (49 final approvals and 6 tentative approvals) from the USFDA.


About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at <http://www.alembicpharmaceuticals.com/>; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APL LTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123